Brief report: effects of methylphenidate on the light adapted electroretinogram

Area of Science:

• Ophthalmology
• Neuroscience
• Pharmacology

Background:

• Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental disorder.
• Methylphenidate is a widely prescribed stimulant medication for ADHD.
• The electroretinogram (ERG) is a diagnostic tool that measures the electrical response of the retina to light.

Purpose of the Study:

• To investigate the impact of methylphenidate on electroretinogram (ERG) parameters in individuals diagnosed with ADHD.
• To explore potential correlations between methylphenidate dosage and ERG changes.

Main Methods:

• Light-adapted ERGs were recorded in five individuals with ADHD (ages 13.6-21.8 years).
• ERG recordings were taken both without medication and 2-6 hours after a slow-release methylphenidate dose (18-60 mg).
• Six flash strengths (71-446 Td.s) were used to evaluate ERG responses, focusing on a-wave and b-wave amplitudes and oscillatory potentials.

Main Results:

• Significant increases in b-wave amplitude (median 27.4%) were observed at a 178 Td.s flash strength in four out of five participants.
• A-wave amplitude showed a median increase of 25.8% at 446 Td.s flash strength.
• Three participants showed increased a-wave amplitude, and two exhibited enhanced oscillatory potentials; one participant on 60 mg methylphenidate showed no distinct ERG changes.

Conclusions:

• The study suggests that methylphenidate can alter ERG a- and b-wave amplitudes in individuals with ADHD.
• ERG measurements may offer valuable insights into the physiological effects of methylphenidate in ADHD patients.
• Further research is warranted to fully elucidate the clinical significance of these ERG findings in ADHD.